| Subjective burden and perspectives of German healthcare workers during the COVID-19 pandemic V Kramer, I Papazova, A Thoma, M Kunz, P Falkai, T Schneider-Axmann, ... European archives of psychiatry and clinical neuroscience 271, 271-281, 2021 | 193 | 2021 |
| Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review E Wagner, S Siafis, P Fernando, P Falkai, WG Honer, A Röh, D Siskind, ... Translational psychiatry 11 (1), 487, 2021 | 109 | 2021 |
| Clozapine augmentation strategies–a systematic meta-review of available evidence. Treatment options for clozapine resistance E Wagner, L Loehrs, D Siskind, WG Honer, P Falkai, A Hasan Journal of psychopharmacology 33 (4), 423-435, 2019 | 107 | 2019 |
| Alteration patterns of peripheral concentrations of cytokines and associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic review and network … S Halstead, D Siskind, M Amft, E Wagner, V Yakimov, ZSJ Liu, K Walder, ... The Lancet Psychiatry 10 (4), 260-271, 2023 | 106 | 2023 |
| Clozapine combination and augmentation strategies in patients with schizophrenia—recommendations from an international expert survey among the Treatment Response and … E Wagner, JM Kane, CU Correll, O Howes, D Siskind, WG Honer, J Lee, ... Schizophrenia bulletin 46 (6), 1459-1470, 2020 | 85 | 2020 |
| Impact of smoking behavior on clozapine blood levels–a systematic review and meta‐analysis E Wagner, L McMahon, P Falkai, A Hasan, D Siskind Acta Psychiatrica Scandinavica 142 (6), 456-466, 2020 | 78 | 2020 |
| Clozapine levels as a predictor for therapeutic response: a systematic review and meta‐analysis D Siskind, M Sharma, M Pawar, E Pearson, E Wagner, N Warren, S Kisely Acta Psychiatrica Scandinavica 144 (5), 422-432, 2021 | 43 | 2021 |
| Characteristics and definitions of ultra-treatment-resistant schizophrenia–a systematic review and meta-analysis M Campana, P Falkai, D Siskind, A Hasan, E Wagner Schizophrenia Research 228, 218-226, 2021 | 43 | 2021 |
| rTMS and tDCS for the treatment of catatonia: a systematic review M Hansbauer, E Wagner, W Strube, A Röh, F Padberg, D Keeser, P Falkai, ... Schizophrenia Research 222, 73-78, 2020 | 42 | 2020 |
| Efficacy of high-frequency repetitive transcranial magnetic stimulation in schizophrenia patients with treatment-resistant negative symptoms treated with clozapine E Wagner, T Wobrock, B Kunze, B Langguth, M Landgrebe, ... Schizophrenia Research 208, 370-376, 2019 | 33 | 2019 |
| Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorders C Okhuijsen-Pfeifer, MZ van der Horst, CA Bousman, B Lin, KR van Eijk, ... Translational Psychiatry 12 (1), 145, 2022 | 29 | 2022 |
| Optical coherence tomography reveals retinal thinning in schizophrenia spectrum disorders E Boudriot, B Schworm, L Slapakova, K Hanken, I Jäger, M Stephan, ... European Archives of Psychiatry and Clinical Neuroscience 273 (3), 575-588, 2023 | 25 | 2023 |
| Cerebrospinal fluid pathologies in schizophrenia-spectrum disorder—a retrospective chart review M Campana, J Strauß, S Münz, T Oviedo-Salcedo, P Fernando, ... Schizophrenia Bulletin 48 (1), 47-55, 2022 | 25 | 2022 |
| Optimising plasma clozapine levels to improve treatment response: an individual patient data meta-analysis and receiver operating characteristic curve analysis K Northwood, E Pearson, U Arnautovska, S Kisely, M Pawar, M Sharma, ... The British Journal of Psychiatry 222 (6), 241-245, 2023 | 24 | 2023 |
| Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST) I Winter-van Rossum, M Weiser, S Galderisi, S Leucht, I Bitter, B Glenthøj, ... The Lancet Psychiatry 10 (3), 197-208, 2023 | 23 | 2023 |
| Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo … A Hasan, A Roeh, S Leucht, B Langguth, M Hansbauer, ... Contemporary Clinical Trials Communications 17, 100537, 2020 | 23 | 2020 |
| Clozapine optimization: a delphi consensus guideline from the treatment response and resistance in psychosis working group E Wagner, D Siskind, P Falkai, O Howes, C Correll, J Lee, WG Honer, ... Schizophrenia bulletin 49 (4), 962-972, 2023 | 22 | 2023 |
| Exercise as an add-on treatment in individuals with schizophrenia: Results from a large multicenter randomized controlled trial I Maurus, L Roell, M Lembeck, I Papazova, D Greska, S Muenz, E Wagner, ... Psychiatry Research 328, 115480, 2023 | 21 | 2023 |
| Psychotropic drugs for the treatment of non-suicidal self-injury in children and adolescents: A systematic review and meta-analysis V Eggart, S Cordier, A Hasan, E Wagner European archives of psychiatry and clinical neuroscience 272 (8), 1559-1568, 2022 | 20 | 2022 |
| Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine E Wagner, WG Honer, IE Sommer, S Koops, DM Blumberger, ... The World Journal of Biological Psychiatry 22 (1), 14-26, 2021 | 20 | 2021 |
